The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
about
Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysisVGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancerClinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.Germline TP53 mutational spectrum in French Canadians with breast cancer.Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progressionNovel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary diseaseAssessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations.Enhanced levels of double-strand DNA break repair proteins protect ovarian cancer cells against genotoxic stress-induced apoptosis.Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.Genomic alterations as mediators of miRNA dysregulation in ovarian cancer.Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.
P2860
Q26776018-0DC1B8E7-1521-489E-A6D9-8CC19A6ED027Q34328133-2526809C-A613-489A-AE0B-875641AB4F6EQ34965421-CDF1C6A1-71E7-42A7-8DC1-744F6CEE453AQ35237915-4330A71C-B8E4-42DB-8BC2-F37CBFDC878DQ35618321-F36D97DE-A367-458F-965E-DAEB21888B43Q35856294-CBC64210-9B4D-4C71-B721-C7D3297048E4Q36248459-F0EAE686-A6CC-426B-BE61-9905BEC5784CQ36910793-C2DE7E3F-ACD3-4A7D-8A40-649D29DE07C9Q37147652-950E750A-1417-45BF-BFF3-0F0A57F390E9Q37359491-5DD43811-C873-4A4A-9239-A68859DEA15AQ37388203-22FF111E-2420-4665-A672-66102B7817E6Q38256465-2FF154E2-25BD-40C6-92EB-F0F372A5FEE7Q39044222-8B2CAD88-2367-40B6-B9E3-C7D0CF2D91C4Q46303839-DA00839D-F12F-4D20-8723-69511B71212AQ49688722-3085CA27-5BE9-4EFA-89E9-4277E9D27AADQ54346442-3632F919-107F-4474-983E-4A7D93C29A85
P2860
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The genomic landscape of TP53 ...... sociated with patient outcome.
@ast
The genomic landscape of TP53 ...... sociated with patient outcome.
@en
The genomic landscape of TP53 ...... sociated with patient outcome.
@nl
type
label
The genomic landscape of TP53 ...... sociated with patient outcome.
@ast
The genomic landscape of TP53 ...... sociated with patient outcome.
@en
The genomic landscape of TP53 ...... sociated with patient outcome.
@nl
prefLabel
The genomic landscape of TP53 ...... sociated with patient outcome.
@ast
The genomic landscape of TP53 ...... sociated with patient outcome.
@en
The genomic landscape of TP53 ...... sociated with patient outcome.
@nl
P2093
P2860
P1433
P1476
The genomic landscape of TP53 ...... sociated with patient outcome.
@en
P2093
Ashley H Birch
Celia M T Greenwood
Diane M Provencher
Jason Madore
Karen Gambaro
Kathleen Klein Oros
Kurosh Rahimi
Manon de Ladurantaye
Michael C J Quinn
Patricia N Tonin
P2860
P304
P356
10.1371/JOURNAL.PONE.0045484
P407
P577
2012-09-20T00:00:00Z